Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Published byΚυρία Γιαννόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at."— Presentation transcript:

1 Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at months 1, 2 and 3. For FACT-Cog higher scores are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BPI-SF lower scores are favourable AAP, abiraterone acetate plus prednisone; BFI-SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ENZ, enzalutamide; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome. Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at months 1, 2 and 3. For FACT-Cog higher scores are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BPI-SF lower scores are favourable AAP, abiraterone acetate plus prednisone; BFI-SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ENZ, enzalutamide; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome. Antoine Thiery-Vuillemin et al. ESMO Open 2018;3:e000397 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at."

Similar presentations

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,
Date of download: 9/20/2016 From: Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer: A Randomized Trial Ann.

Date of download: 9/20/2016 From: Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer: A Randomized Trial Ann.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
LUX-Lung 3 clinical trial

LUX-Lung 3 clinical trial
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With.

An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With.
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration- Resistant Prostate Cancer  Antonio Macciò, MD  Journal of Pain and.

A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration- Resistant Prostate Cancer  Antonio Macciò, MD  Journal of Pain and.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.
Quality-of-life scores in neurogenic thoracic outlet syndrome patients undergoing first rib resection and scalenectomy  Danielle H. Rochlin, BA, Marta.

Quality-of-life scores in neurogenic thoracic outlet syndrome patients undergoing first rib resection and scalenectomy  Danielle H. Rochlin, BA, Marta.
Volume 54, Issue 2, Pages (August 2008)

Volume 54, Issue 2, Pages (August 2008)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Capture, Transfer, and Feedback of Patient-Centered Outcomes Data in Palliative Care Populations: Does It Make a Difference? A Systematic Review  Simon.

Capture, Transfer, and Feedback of Patient-Centered Outcomes Data in Palliative Care Populations: Does It Make a Difference? A Systematic Review  Simon.
Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.

Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.
Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.

Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.
Stacy D. Sanford, PhD, Jennifer L

Stacy D. Sanford, PhD, Jennifer L
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Similar presentations

Ads by Google